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One of the most frequently encountered heterocycles in medic-
inal chemistry is 4(3H)-quinazolinone (1, Fig. 1) having broad
range of biological activities (Kamal et al., 2006, 2010; Laddha
et al., 2009; Malawska, 2005; Padala et al., 2003; Clercq, 2002;
Nawrocka and Stasko, 2002; Sinha and Srivastava, 1994).
Among the various classes of 4(3H)-quinazolinones, 2-styryl
substituted derivatives (2, Fig. 1) have been gaining prominence
due to the fact that its derivatives have been found to possess a
wide spectrum of activities, such as tubulin polymerization
inhibitor (Raffa et al., 2004), cytotoxic agent (Liu et al.,
2006), Hsp90 inhibitor (Sgobba and Rastelli, 2009; Park
et al., 2007), anticonvulsant (Bhandari et al., 2008; Welch
Figure 1 General structure of 4(3H)-quinazolinone and 2-styryl-
4(3H)-quinazolinone.
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Anti-proliferative (Mrozek-Wilczkiewicz et al., 2010) antibac-
terial, and antifungal agent (Gupta et al., 2008; Jatav et al.,
2008c). Moreover, thiazoles are important pharmacodynamic
heterocyclic nuclei, which when incorporated in different het-
erocyclic templates have been reported to possess various bio-
logical activities (Siddiqi and Ahsan, 2010 Li et al., 2009;
Holla et al., 2003; Nora De Souza,2005; Hsu et al., 2003). More
speciﬁcally, diverse pharmacological activities can be achieved
by incorporating thiazole moiety at 3rd position of quinazo-
lin-4(3H)-ones (Kumar et al., 2007; Maarouf et al., 2004;
Kumar et al., 1997).
Microwave-assisted organic reactions are now well estab-
lished and have gained popularity as indicated by large num-
ber of papers currently published on this topic (Caddick and
Fitzmaurice, 2009; Kappe and Dallinger, 2009; Jindal and
Bajaj, 2008; Katritzky and Singh, 2003; Lidstro¨m et al.,
2001). Some of the interesting features of this method are
milder reaction conditions, reduction of reaction times, en-
hanced selectivity, and associated ease of manipulation. In
the light of the above observations, it was thought worthwhile
to synthesize a new series of 2-styryl quinazolin-4(3H)-one
derivatives by incorporating the thiazole moiety at 3rd position
using microwave irradiation.
2. Results and discussion
2.1. Chemistry
Although there are many reports describing the synthesis of
4(3H)-quinazolinones (1), most of these approaches are limited
in that only phenyl group at R1 is tolerated (Connolly et al.,
2005). There are only a few speciﬁc reports on the preparation
of the 3-substituted 2-styryl quinazolin-4(3H)-ones (2) (Raffa
et al., 2004; Liu et al., 2006; Connolly et al., 2005; Wolfe
et al., 1990; Philipova et al., 2006). The general method for
the synthesis of these derivatives is the Knoevenagel condensa-
tion of 2-methylsubstituted quinazolinones (3) with aromatic
aldehydes under basic (Wolfe et al., 1990; Philipova et al.,
2006) or acidic (Raffa et al., 2004) conditions (Scheme 1).
However, this method requires more number of steps which
eventually lead to the lower yields (Raffa et al., 2004; WolfeScheme 1 General route for the synthesis of 2et al., 1990; Philipova et al., 2006). Furthermore, it proceeds
via highly moisture sensitive and irritant intermediate 2-
methyl-4H-benzo[d][1,3]oxazin-4-one (4) (Madkour, 2004),
which requires a special care in its handling and storage. A
new strategy was therefore planned, where 2-styryl benzoxazi-
nones (5) and 2-aminothiazoles (6) were condensed to give the
title compounds (7). 2-Styryl benzoxazinones were conve-
niently prepared by following the reported method (Fathalla
et al., 2008) and were highly stable as compared to compound
(4).
As far as the microwave assisted methods for the synthesis
of quinazolinones are concerned, most of them have been re-
ported for either 2 or 3 substituted derivatives (Bakavoli
et al., 2007; Li et al., 2007; Rad-Moghadam and Mohseni,
2003; Rad-Moghadam et al., 2006). There are reports on the
synthesis of 2,3-disubstituted quinazolinone using microwave
irradiation but, most of them either involve the use of alkyl
orthoesters (Ighilahriz et al., 2008; Dabiri et al., 2004; Lingaiah
et al., 2006) or cyclic amides (Shankaraiah et al., 2009), which
limit the variety of substitutions at 2nd position. Liu et al.,
(2007) reported one pot microwave assisted method for the
generation of library of 2-styryl quinazolinones using
P(OPh)3 and pyridine. However, the yields were low to moder-
ate (7.4–51%). Another drawback using P(OPh)3 was its re-
moval from the product. It could not be separated using
simple puriﬁcation procedures like washing or crystallization.
Recently, Zhou et al. (2004) have developed a general meth-
od for the synthesis of 3-sulfonamide-substituted quinazoli-
none derivatives by condensation of benzoxazinones (5) and
substituted sulfonyl hydrazides under solvent free conditions
at 130 C. It was envisaged that this methodology could be ex-
tended to the preparation of the title compounds (7) under
microwave irradiation. However, this protocol did not work
under microwave irradiation when applied to (E)-2-styryl-
4H-benzo[d][1,3]oxazin-4-one (5a) and 2-amino-5-methylthia-
zole (6a). Therefore, it was decided to use DMF as a solvent
in above reaction because of its good solvating property and
high loss tangent (Lidstro¨m et al., 2001). The reaction was suc-
cessfully completed within 6 min of microwave irradiation at
350 W. The required compound (7a) was isolated in 40% yield
along with 35% of diamide (8) after column chromatographic
puriﬁcation. The isolation of compound (8) suggests that the
reaction might have proceeded with formation of this
compound (Zhou et al., 2004).
Furthermore, the yield of the desired product could be
improved if complete conversion of diamide to quinazolinone
is possible. There are many instances which report the cycliza-
tion of diamides to quinazolinones under basic conditions
(Brunton et al., 2008; Kshirsagar et al., 2007; He and Snider,
1999). In some cases, pyridine has also been used for conden-
sation of benzoxazinones with amines (Madkour, 2004;
Laddha et al., 2006; Al-Obaid et al., 2009) to corresponding
quinazolinones. However, the reaction proceeded sluggishly-styryl-3-substituted quinazolin-4(3H)-ones.
Table 2 Microwave assisted synthesis of 3-thiazole-substi-
tuted 2-styrylquinazolin-4(3H)-ones at 350 W
Compd No. R Ar Reaction time
(min)
Yielda
(%)
7a Me Ph 7 78
7b Br Ph 7 70
7c Br 4-OMe-Ph 8 68
7d Br 2-NO2-Ph 6 75
7e Br 3-NO2-Ph 7 69
7f Br 4-NO2-Ph 6 72
7g Br 4-Cl-Ph 8 67
7h Br 4-Me-Ph 8 69
7i Br 2,3,4-Tri-OMe-Ph 9 54
7j H 4-Me-Ph 7 80
7k Me 2-NO2-Ph 5 84
7l Me 3-NO2-Ph 6 81
a Isolated yields after recrystallization.
Table 3 Zone of growth inhibition in mm
Compd
No.
Gram negative Gram positive Fungus
E. coli P. aeruginosa B. megaterium B. subtilis A. niger
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uted to the less dielectric constant of pyridine. Therefore, we
decided to use mixture of DMF and pyridine as solvent. In
preliminary experiments with many different solvent ratios
and power levels of microwave irradiation, we observed that
the most favorable one was DMF:Py (2:1) at 350 W of micro-
wave irradiation (Table 1, entry 4), which not only afforded
the product in good yield, but also with better reaction rates.
All the quinazolinone derivatives (7a–7l) were synthesized
using these optimized reaction conditions (Scheme 2). The
reaction time and yield for the different substitutions used to
synthesize variety of 3-thiazole substituted 2-styrylquinazo-
lin-4(3H)-ones are given in Table 2.
2.2. Antibacterial and antifungal activity
The in vitro antibacterial and antifungal activity of title com-
pounds was determined using cup-plate agar diffusion method
(Colins and Lyne, 1970; Dixit et al., 2010). The nearest zone of
inhibition was measured in mm. The concentration (50 lg/mL)
of test compounds was prepared by dissolving the compounds
in dimethyl sulfoxide (DMSO). Under identical conditions,
norﬂoxacin and clotrimazole were tested as standard drug
(50 lg/mL) for bacteria and fungi, respectively. Antibacterial
and antifungal activities shown by moderately active com-
pounds toward Escherichia coli (ATCC 25922), Pseudomonas
aeruginosa (ATCC 27853) (Gram-negative bacteria), BacillusTable 1 Optimization of reaction conditions using co-solvent
for the synthesis of (E)-3-(5-methylthiazol-2-yl)-2-styrylquinaz-
olin-4(3H)-one (7a) under microwave irradiation
Entry Solvent ratio
DMF:Py
Power
(W)
Reaction time
(min)
Yielda
(%)
1 1:0 350 6 40
2 1:2 350 13 71
3 1:1 350 12 75
4 2:1 350 7 78
5 2:1 280 15 77
6 2:1 420 6 72
a Isolated yield after recrystallization except entry 1 where col-
umn chromatography was used.
Scheme 2 Proposed route for the synthesis of 2-styryl-3-megaterium (ATCC 9885), Bacillus subtilis (ATCC 6633)
(Gram-positive bacteria), and Aspergillus niger (ATCC
16404) (Fungus) are recorded in Table 3.thiazole substituted quinazolin-4(3H)-one derivatives.
7a 12 10 9 12 4
7b 18 12 11 17 12
7c – 4 – – –
7d 16 – 7 15 10
7e 14 14 10 – –
7f 13 9 6 8 5
7g 10 – 13 10 14
7h – 6 4 7 13
7i 8 4 – – –
7j 5 – – 6 –
7k 12 10 9 13 9
7l 10 9 8 – –
NFa 20 18 17 22 –
CTb – – – – 24
a Norﬂoxacin.
b Clotrimazole.
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compounds have lesser activity than corresponding standard
used. However, against E. coli compounds (7b) and (7d);
against P. aeruginosa compound (7e); against B. megaterium
compound (7g); against B. subtilis compound (7b) have com-
parable activity with standard. Antifungal study revealed that
most of the compounds were not found sufﬁciently active to
inhibit A. niger as compared to standard. Though, compound
(7g) was found to have higher activity among all tested
compounds.3. Experimental
The MW experiments were carried out at atmospheric pressure
in a glass vessel prolonged by a condenser and were performed
using Scientiﬁc Microwave Synthesis System, (Catalyst Sys-
tems, Model: CATA-R). Melting points were determined by
open capillary method and are uncorrected. The elemental
analyses (C, H and N) were performed on an Elemental Vario
EL analyzer and the results are within ±0.4% of the calcu-
lated values. Infrared spectra were recorded in the range of
4000–400 cm1 using KBr with a Perkin–Elmer spectrum
GX spectrophotometer (FT-IR) instrument. 1H NMR and
13C NMR spectra were recorded on a Bruker (400 MHz)
instrument using DMSO-d6 as a solvent as well as an internal
reference standard; the chemical shifts are given in ppm (d).
The mass spectra (EI-MS) were recorded on a Shimadzu
LC–MS 2010 eV mass spectrophotometer in acetonitrile. The
progress of reactions and puriﬁcations was monitored by
TLC plates (UV detection) on aluminium sheets coated with
Silica Gel 60 F254 (Merck). All common reagents and solvents
were purchased from commercial sources and were used with-
out further puriﬁcation, while the starting materials cinnamic
acid derivatives (Koo et al., 1963) and cinnamoyl chloride
derivatives (Womack and McWhirter, 1955) were synthesized
by reported method. 2-Aminothiazole and 2-amino-5-methyl-
thiazole were purchased from Sigma–Aldrich Inc., Mumbai.
3.1. General procedure for the synthesis of (E)-2-styryl-
substituted 4H-benzo[d][1,3]oxazin-4-one derivatives (5)
The benzoxazinone derivatives were prepared by following the
reported method (Fathalla et al., 2008). Accordingly, anthra-
nilic acid (1.37 g, 0.01 mol) contained in a round bottomed
ﬂask was dissolved in freshly dried pyridine (5 mL). To the
above solution, appropriate cinnamoyl chloride derivative
(0.02 mol) was added drop wise under stirring, over a period
of 15 min. The reaction mass was then allowed to stand for
additional 2 h, with occasional shaking. It was then poured
into 100 mL ice cold water. The solid thus obtained was ﬁl-
tered, washed with cold water, and recrystallized from ethanol.
The yields were in the range of 66–92%.
3.2. General procedure for the synthesis of 2-amino-5-
bromothiazole (6c)
In a round bottomed ﬂask, 2-aminothiazole (6b) (10.01 g,
0.1 mol) was dissolved in 75 mL of glacial acetic acid. To the
above stirred solution, bromine (5.1 mL, 0.1 mol) in 15 mL
of glacial acetic acid was added drop wise. The reaction mass
was additionally stirred for 30 min at room temperature andwas poured in 500 mL ice-cold water. The product was ex-
tracted with ethyl acetate (3 · 100 mL) and was washed succes-
sively with 10% HCl solution (2 · 70 mL) and distilled water
(2 · 70 mL). The solvent was then evaporated and the product
thus obtained was recrystallized from ethanol. The yield of the
product was 79% and it decomposed in the range of 115–
117 C.
3.3. General microwave assisted procedure for the synthesis of
3-thiazole-substituted 2-styrylquinazolin-4(3H)-ones (7a–7l)
Appropriate benzoxazinone (5) (0.02 mol) and 2-aminothia-
zole derivative (6) (0.02 mol) were taken in a solution of
DMF (1 mL) and pyridine (0.5 mL) contained in a two-neck
round bottomed ﬂask ﬁtted with a device condenser. The mix-
ture was then heated under microwave irradiation at 350 W for
an appropriate time (Table 2). After cooling, the reaction mass
was dissolved in ethyl acetate (40 mL) and washed with dis-
tilled water (20 mL), dil. HCl (2 · 20 mL), aq. NaHCO3
(2 · 20 mL) and distilled water (20 mL) sequentially by li-
quid–liquid extraction. The organic layer was dried and the
resulting product was further puriﬁed by recrystallization from
THF. Yields are given in Table 2.
3.4. (E)-3-(5-Methylthiazol-2-yl)-2-styrylquinazolin-4(3H)-
one (7a)
Mp 172–175 C. IR (KBr) m max/cm1: 1695 (C‚O str.), 1585
(C‚N str.), 1632 (C‚C str.), 675 (C–S str.), 1385 (C–H bend).
1H NMR (DMSO-d6): d 2.36 (s, 3H, CH3), 6.93 (d,
J= 15.6 Hz, 1H, CH styryl), 7.20–7.24 (m, 2H, ArH and
CH thiazole), 7.42–7.44 (m, 3H, ArH), 7.55 (t, J= 7.6 Hz,
1H, ArH), 7.62 (d, J= 15.6 Hz, 1H, CH styryl), 7.7 (d,
J= 6.8 Hz, 2H, ArH), 7.94 (d, J= 7.2 Hz, 1H, ArH), 8.3
(d, J= 7.6 Hz, 1H, ArH). 13C NMR (DMSO-d6): d 11.82,
122.31, 122.84, 123.74, 123.80, 126.15, 128.54, 129.4, 130.15,
130.40, 132.58, 135.01, 138.72, 141.39, 147.32, 160.34, 164.06.
MS-EI (70 eV): m/z 345.4 (M+). Anal. Calcd. for C20H15
N3OS: C, 69.54; H, 4.38; N, 12.17%. Found: C, 69.55; H,
4.29; N, 12.29%.
3.5.(E)-3-(5-Bromothiazol-2-yl)-2-styrylquinazolin-4(3H)-one
(7b)
Mp 195–197 C. IR (KBr) m max/cm1: 1684 (C‚O str.), 1593
(C‚N str.), 1634 (C‚C str.), 678 (C–S str.), 564 (C–Br str.).
1H NMR (DMSO-d6): d 6.91–6.94 (m, 2H, CH thiazol and
CH styryl), 7.20–7.24 (m, 2H, ArH), 7.43–7.55 (m, 3H,
ArH), 7.68–7.73 (m, 2H, CH styryl and ArH), 8.3 (d,
J= 7.6 Hz, 1H, ArH). 13C NMR (DMSO-d6): d 119.86,
120.27, 122.13, 126.62, 127.53, 127.92, 128.01, 128.11, 128.43,
132.73, 136.32, 137.04, 138.78, 146.03, 147.15, 160.23, 167.43.
MS-EI (70 eV): m/z 408.3 (M+), 410.3 (M+2). Anal. Calcd.
for C19H12BrN3OS: C, 55.62; H, 2.95; N, 10.24%. Found: C,
55.69; H, 2.99; N, 10.29%.
3.6. (E)-3-(5-Bromothiazol-2-yl)-2-(4-methoxystyryl)quinazo-
lin- 4(3H)-one (7c)
Mp 212–215 C. IR (KBr) m max/cm1: 1686 (C‚O str.), 1595
(C‚N str.), 1635 (C‚C str.), 672 (C–S str.), 569 (C–Br str.),
2813 (Ar–O–CH3), 1384 (C–H bend.).
1H NMR (DMSO-d6):
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ArH), 7.32–7.54 (m, 4H, ArH), 7.69–7.74 (m, 2H, CH styryl
and ArH), 8.29 (d, J= 7.6 Hz, 1H, ArH). 13C NMR
(DMSO-d6): d 57.01, 114.01, 120.27, 120.74, 122.13, 126.42,
127.53, 128.01, 128.43, 128.71, 136.32, 137.04, 137.63, 146.03,
147.23, 160.14, 160.23, 167.43. MS-EI (70 eV): m/z 439.2
(M+), 441.2 (M+2). Anal. Calcd. for C20H14BrN3O2S: C,
54.56; H, 3.20; N, 9.54%. Found: C, 54.43; H, 3.12; N, 9.51%.
3.7. (E)-3-(5-Bromothiazol-2-yl)-2-(2-nitrostyryl)quinazolin-
4(3H)-one (7d)
Mp 277–240 C. IR (KBr) m max/cm1: 1681 (C‚O str.), 1594
(C‚N str.), 1630 (C‚C str.), 678 (C–S str.), 562 (C–Br str.),
1543 and 1393 (N‚O str.). 1H NMR (DMSO-d6): d 6.92 (s,
1H, CH thiazole), 7.15 (d, J= 15.6, 1H, CH styryl), 7.31 (t,
J= 8 Hz, 1H, ArH), 7.5–7.56 (m, 3H, ArH), 7.67 (d,
J= 15.6, 1H, CH styryl), 7.88 (t, J= 7.6, 1H, ArH), 8.02–
8.14 (m, 3H, ArH). 13C NMR (DMSO-d6): d 120.27, 122.13,
122.62, 127.14, 127.22, 127.53, 128.01, 128.43, 129.07, 130.11,
130.14, 131.59, 136.32, 137.04, 145.27, 146.03, 148.02, 160.23,
167.43. MS-EI (70 eV): m/z 454.1 (M+), 456.1 (M+2). Anal.
Calcd. for C19H11BrN4O3S: C, 50.12; H, 2.44; N, 12.31%.
Found: C, 50.24; H, 2.39; N, 12.39%.
3.8. (E)-3-(5-Bromothiazol-2-yl)-2-(3-nitrostyryl)quinazolin-
4(3H)-one (7e)
Mp 247–250 C. IR (KBr) m max/cm1: 1680 (C‚O str.), 1593
(C‚N str.), 1631 (C‚C str.), 679 (C–S str.), 563 (C–Br str.),
1545 and 1389 (N‚O str.). 1H NMR (DMSO-d6): d 6.92 (s,
1H, CH thiazole), 7.12 (d, J= 15.6, 1H, CH styryl), 7.51–
7.54 (m, 2H, ArH), 7.65 (d, J= 15.6, 1H, CH styryl), 7.72–
7.84 (m, 2H, ArH), 8.1–8.32 (m, 3H, ArH), 8.46 (s, 1H,
ArH). 13C NMR (DMSO-d6): d 119.53, 120.27, 121.84,
122.13, 124.32, 125.28, 127.53, 128.01, 128.43, 133.78, 136.07,
136.32, 137.04, 139.41, 146.03, 146.91, 147.22, 160.23, 167.43.
MS-EI (70 eV): m/z 454.2 (M+), 456.2 (M+2). Anal. Calcd.
for C19H11BrN4O3S: C, 50.12; H, 2.44; N, 12.31%. Found:
C, 50.02; H, 2.36; N, 12.37%.
3.9. (E)-3-(5-Bromothiazol-2-yl)-2-(4-nitrostyryl)quinazolin-
4(3H)-one (7f)
Mp 264–267 C. IR (KBr) m max/cm1: 1681 (C‚O str.), 1594
(C‚N str.), 1630 (C‚C str.), 678 (C–S str.), 562 (C–Br str.),
1542 and 1394 (N‚O str.). 1H NMR (DMSO-d6): d 6.92 (s,
1H, CH thiazole), 7.14 (d, J= 15.6, 1H, CH styryl), 7.54–
7.69 (m, 3H, CH styryl and ArH), 7.88 (d, J= 8.8 Hz, 2H,
ArH), 7.99–8.13 (m, 2H, ArH), 8.24 (d, J= 8.8 Hz, 2H,
ArH). 13C NMR (DMSO-d6): d 120.27, 121.23, 122.13,
123.67, 127.53, 128.01, 12819, 128.43, 136.32, 137.04, 137.78,
139.91, 146.03, 146.57, 148.32, 160.23, 167.43. MS-EI
(70 eV): m/z 454.1 (M+), 456.1 (M+2). Anal. Calcd. for
C19H11BrN4O3S: C, 50.12; H, 2.44; N, 12.31%. Found: C,
49.99; H, 2.46; N, 12.40%.
3.10. (E)-3-(5-Bromothiazol-2-yl)-2-(4-chlorostyryl)quinazo-
lin-4(3H)-one (7g)
Mp 270–274 C. IR (KBr) m max/cm1: 1688 (C‚O str.), 1595
(C‚N str.), 1633 (C‚C str.), 671 (C–S str.), 566 (C–Br str.),1382 (C–H bend.). 1H NMR (DMSO-d6): d 6.9–6.93 (m, 2H,
CH thiazole and CH styryl), 7.18 (dt, J= 7.6, 1.3 Hz, 1H,
ArH), 7.51–7.59 (m, 4H, CH styryl and ArH), 7.75–7.78 (m,
2H, ArH), 8.31 (dd, J= 7.6, 1.3 Hz, 2H, ArH). 13C NMR
(DMSO-d6): d 120.27, 121.42, 122.13, 127.29, 127.53, 128.01,
128.43, 129.62, 132.66, 134.43, 136.32, 137.61, 137.04, 146.03,
146.61, 160.23, 167.43. MS-EI (70 eV): m/z 443.1 (M+),
445.1 (M+2), 447.1 (M+4). Anal. Calcd. for C19H11BrN3OS:
C, 51.31; H, 2.49; N, 9.45%. Found: C, 51.25; H, 2.47; N,
9.41%.
3.11. (E)-3-(5-Bromothiazol-2-yl)-2-(4-methylstyryl)quinazo-
lin-4(3H)-one (7h)
Mp 212–215 C. IR (KBr) m max/cm1: 1688 (C‚O str.), 1595
(C‚N str.), 1633 (C‚C str.), 671 (C–S str.), 566 (C–Br str.),
1382 (C–H bend.). 1H NMR (DMSO-d6): d 2.35 (s, 3H,
CH3), 6.67 (d, J= 16 Hz, 1H, CH styryl), 6.92 (s, 1H, CH thi-
azole), 7.18 (t, J= 7.6 Hz, 1H, ArH), 7.33 (d, J= 8 Hz, 2H,
ArH), 7.62 (dd, J= 7.6, 1.3 Hz, 1H, ArH), 7.71–7.80 (m,
4H, CH styryl and ArH), 8.02 (d, J= 7.6 Hz, 1H, ArH). 13C
NMR (DMSO-d6): d 20.44, 120.27, 120.59, 122.13, 127.53,
127.68, 127.84, 128.01, 128.43, 132.37, 136.32, 136.81, 137.04,
141.51, 146.03, 147.05, 160.23, 167.43. MS-EI (70 eV): m/z
423.0 (M+), 425.0 (M+2). Anal. Calcd. for C20H14BrN3OS:
C, 56.61; H, 3.33; N, 9.90%. Found: C, 56.68; H, 3.28; N,
9.87%.
3.12. (E)-3-(5-Bromothiazol-2-yl)-2-(3,4,5-trimethoxystyryl)-
quinazolin-4(3H)-one (7i)
Mp 240–242 C (d). IR (KBr) m max/cm1: 1689 (C‚O str.),
1598 (C‚N str.), 1634 (C‚C str.), 674 (C–S str.), 569 (C–Br
str.), 2810 (Ar–O–CH3), 1382 (C–H bend.).
1H NMR
(DMSO-d6): d 3.87 (s, 3H, OCH3), 3.90 (s, 6H, (OCH3)2),
6.54 (d, J= 16 Hz, 1H, CH styryl), 6.91 (s, 1H, CH thiazole),
6.93 (s, 2H, ArH), 7.02 (t, J= 7.6 Hz, 1H, ArH), 7.48 (d,
J= 7.6 Hz, 1H, ArH), 7.59 (t, J= 7.6 Hz, 1H, ArH), 7.8 (d,
J= 16 Hz, 1H, CH styryl), 8.16 (d, J= 7.6 Hz, 1H, ArH).
13C NMR (DMSO-d6): d 61.03, 66.24, 103.65, 119.46,
120.27, 122.13, 127.53, 128.01, 128.43, 130.17, 136.32, 137.04,
141.44, 141.53, 146.03, 147.15, 152.55, 160.23, 167.43. MS-EI
(70 eV): m/z 499.1 (M+), 501.1 (M+2). Anal. Calcd. for
C22H18BrN3O4S: C, 52.81; H, 3.63; N, 8.40%. Found: C,
52.87; H, 3.66; N, 8.38%.
3.13.(E)-2-(4-Methylstyryl)-3-(thiazol-2-yl)quinazolin-4(3H)
-one(7j)
Mp 176–178 C. IR (KBr) m max/cm1: 1686 (C‚O str.), 1595
(C‚N str.), 1634 (C‚C str.), 675 (C–S str.), 565 (C–Br str.),
1382 (C–H bend.). 1H NMR (DMSO-d6): d 2.34 (s, 3H,
CH3), 6.67 (d, J= 16 Hz, 1H, CH styryl), 6.62 (d,
J= 3.2 Hz, 1H, CH thiazole), 7.08 (d, J= 3.2 Hz, 1H, CH thi-
azole), 7.18 (t, J= 7.6 Hz, 1H, ArH), 7.33 (d, J= 8 Hz, 2H,
ArH), 7.62 (dd, J= 7.6, 1.3 Hz, 1H, ArH), 7.71–7.80 (m, 4H,
CH styryl and ArH), 8.02 (d, J= 7.6 Hz, 1H, ArH). 13C
NMR (DMSO-d6): d 20.44, 112.23, 120.56, 122.13, 127.53,
127.67, 127.85, 128.01, 128.43, 132.35, 136.32, 136.83, 137.48,
141.52, 146.03, 147.08, 160.23, 164.92. MS-EI (70 eV): m/z
345.3 (M+). Anal. Calcd. for C20H15N3OS: C, 69.54; H,
4.38; N, 12.17%. Found: C, 67.87; H, 4.66; N, 12.38%.
368 C.L. Jagani et al.3.14. (E)-3-(5-Methylthiazol-2-yl)-2-(2-nitrostyryl)quinazolin-
4(3H)-one (7k)
Mp 221–224 C. IR (KBr) m max/cm1: 1685 (C‚O str.), 1596
(C‚N str.), 1632 (C‚C str.), 673 (C–S str.), 566 (C–Br str.),
1382 (C–H bend.). 1H NMR (DMSO-d6): d 2.36 (s, 3H,
CH3), 7.14 (d, J= 15.6, 1H, CH styryl), 7.24 (s, 1H, CH thi-
azole), 7.33 (t, J= 8 Hz, 1H, ArH), 7.5–7.56 (m, 3H, ArH),
7.66 (d, J= 15.6, 1H, CH styryl), 7.87 (t, J= 7.6, 1H,
ArH), 8.02–8.14 (m, 3H, ArH). 13C NMR (DMSO-d6): d
11.82, 122.13, 122.61, 122.84, 127.15, 127.23, 127.53, 128.01,
128.43, 129.09, 130.11, 130.16, 131.59, 135.01, 136.32, 145.28,
146.03, 148.04, 160.23, 164.06. MS-EI (70 eV): m/z 390.2
(M+). Anal. Calcd. for C20H14N4O3S: C, 61.53; H, 3.61; N,
14.35%. Found: C, 60.24; H, 3.39; N, 14.78%.
3.15. (E)-3-(5-Methylthiazol-2-yl)-2-(3-nitrostyryl)quinazolin-
4(3H)-one (7l)
Mp 229–231 C. IR (KBr) m max/cm1: 1689 (C‚O str.), 1598
(C‚N str.), 1630 (C‚C str.), 678 (C–S str.), 1384 (C–H
bend.), 1542 and 1398 (N‚O str.). 1H NMR (DMSO-d6): d
2.36 (s, 3H, CH3), 7.12 (d, J= 15.6, 1H, CH styryl), 7.23 (s,
1H, CH thiazole), 7.51–7.54 (m, 2H, ArH), 7.65 (d,
J= 15.6, 1H, CH styryl), 7.72–7.84 (m, 2H, ArH), 8.1–8.32
(m, 3H, ArH), 8.46 (s, 1H, ArH). 13C NMR (DMSO-d6): d
11.82, 119.53, 121.84, 122.13, 122.84, 124.32, 125.28, 127.53,
128.01, 128.43, 133.78, 135.01, 136.07, 136.32, 139.41, 146.03,
146.92, 147.24, 160.23, 164.06. MS-EI (70 eV): m/z 390.1
(M+). Anal. Calcd. for C20H14N4O3S: C, 61.53; H, 3.61; N,
14.35%. Found: C, 61.02; H, 3.36; N, 14.77%.4. Conclusions
In summary, in the present study we have successfully synthe-
sized a series of novel 3-thiazole substituted 2-styryl-4(3H)-
quinazolinone derivatives (7a–7l) in good yield using
pyridine-DMF as co-solvent under microwave irradiation.
The use of combination of solvent under optimized microwave
conditions leads to the formation of products (7a–7l) with
improved yields, shorter reaction time, and drastic reduction
of formation of diamide (8). The antimicrobial activities of
the synthesized compounds showed that compounds (7b),
(7d), and (7g) have comparable inhibitory effects with the
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